Page 1920 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Index 1347

novel modes of, 434–439 Metabolic acidosis, 932 Monomorphic ventricular tachycardia,
addressing improved patient ventilator in acute kidney injury, 932 284–285
interactions, 437–438, 438f bicarbonate therapy of, 261 Monotherapy, 547
clinical challenges facing clinicians, Metabolic alkalosis, 932, 951 Morbidity, preventing, in intensive-care unit,
434–435, 434f acid-base balance and, 973 32–37, 33f, 35f, 36f
strategies addressing challenge of in acute kidney injury, 932 integrated approach to patient safety, 36
balancing gas exchange versus vili, Metabolic disorders, specific, 969–970 preventable versus inevitable harm, 32
435–437 Metabolic disturbances, acid-base safety, taxonomy of patient issues,
in pregnancy, 1267–1268, 1267t balance and, 969 33–36, 34t, 35f
sleep and, 159–160 Metabolic emergencies, 877–878, 878f Morel-Lavallee lesion, 1172, 1172f
Meckel diverticulum, 1021 Metabolic management in head injury, Morphine, 150–151
Medical anthropologists, use of narrative 1136–1137 Mortality probability model 0 at zero hours,
by, 116 glycemic control in, 1136–1137 sepsis and, 569
Medical dermatoses, 1290–1296 thyroid function in, 1137 Mortality Probability Model (MPM) scoring
bullous pemphigoid, 1292, 1292f Metabolism, sepsis and, 574 system, 89
edema bullae, 1295–1296, 1296f Methanol, 1208 Mortality Probability Model (MPM II) scoring
erythroderma, 1293, 1293ft Methemoglobinemia, 1218–1219 system, 85, 88, 91
graft-versus-host disease, 1294–1295 Methicillin-resistant Staphylococcus aureus Motility agents, 137
pemphigus vulgaris, 1290–1292, 1291f (MRSA), 559 Motility as host defense, 704
psoriasis, 1292–1293, 1292f Methodologic rigor, 85 Mucomycosis, 976
purpura, 1294 Methotrexate, use of, in critically ill Multidetector computed tomography
Medical informatics, 49–50 patient, 1251 (MDCT), 1141
Medical schools and residency programs, Methotrexate pneumonitis, rheumatoid Multidrug resistant tuberculosis
teaching critical care in arthritis and, 1244 (MDR-TB), 635
curricula of, 6 Methylprednisolone, spinal injuries Multifactorial respiratory failure,
Medical surge and, 1150 487–495, 492t
intensive-care unit exercises related to MHLA-DR, 555–556 Multinational Association for Supportive Care
needs for, 58 Microcosting, 42 in Cancer (MASCC), 603
modeling for patients and resources, 58–59 Microhematuria, 1166 Multiorgan donor, 1108–1115
Medication-induced thrombocytopenia, Microscopic injury, 440–441 declaration of brain death, 1109
850–851, 850t, 851t Microvascular pressure, 1048 evaluation of potential, 1110–1113
Midazolam, 152
cardiac evaluation, 1111–1112, 1112t
MELD score, 223 https://kat.cr/user/tahir99/
Meleney gangrene, 690, 691 for refractory status epilepticus, 786 donor-related malignancies,
Meleney ulcers, 691 for status epilepticus, 785 1111, 1112t
Meningitis, 638, 837 Miliaria, 1304, 1304f liver, 1113
bacterial, 652 Miliaria crystallina, 1304, 1304f pulmonary, 1112–1113, 1112t
clinical presentation, 652–658, 653–654 Minimal conscious, 830 renal, 1113, 1113f
diagnosis of, 654 Minitracheostomy, 395 screening for infectious agents,
due to aerobic gram negative bacilli, 653 Mirizzi syndrome, 999 1110–1111, 1111t
epidemiology and etiology, 652–653, 652t Mitochondrial myopathy, 828 management of, 1113–1115
pneumococcal, 652–653 Mitral regurgitation, 350–351, 350f request for consent, 1109–1110
prevention, 657–658 clinical presentation in, 350–351 Multiorgan dysfunction, effects of, 1237
sickle cell disease and, 911 diagnostic evaluation in, 351 Multiple autoantibodies and multisystem
treatment of, 654–657, 654f, 655t, 656t etiology in, 350 inflammatory disease, 1245
Meningococcemia, 1298–1299, 1299f, 1300ft management of, 351 Multiple-dose activated charcoal
Meningococcus, infection control and, 31 pathophysiology in, 350 (MDAC), 1204
Meperidine, 151 Mitral stenosis, 348–350 Multiple myeloma, 947
Mephedrone (4-MMC), 560 clinical presentation of, 349 Multiple Organ Dysfunction Score
Meropenem, 546 diagnostic evaluation of, 349 (MODS), 89
MERS-CoV, 720 management of, 349 Multisystem trauma
Mesenteric ischemia, 1036–1044, 1037t pathophysiology of, 348–349, 349f deciding on surgical intervention, 1121
anatomy and dynamics of mesenteric Mitral valve, systolic anterior motion priorities in, 1116–1121
circulation, 1036–1037, 1037f of, 1069 adequacy of perfusion, 1118–1119, 1119t
clinical presentation of, 1039–1040 Mitral valve operations, 1069 airway, oxygenation, ventilation, and
control of circulation, 1037–1038, 1038t Mixed antagonists response syndrome cervical spine control, 1117
diagnosis of acute, 1040–1042, 1040f, 1041f (MARS), 551 cervical spine protection, 1118
intestinal risk factors, 1039 Mobile computing, 52–53, 53f detailed systematic assessment and
management of, 1042–1043 Mobility, sepsis and, 575 definitive care, 1120
nonocclusive, 1039 Mobilization of critically ill patient, 163 fracture stabilization, 1120
pathophysiology of intestinal ischemia, 1038 Model of End-Stage Liver Disease locating source of internal
prognosis, thyroid function, 1037 (MELD), 1097 hemorrhage, 1119
systemic response to Models of quality, 11 neurologic status, 1119–1120
revascularization, 1039 Modular Emergency Medical System reevaluation and monitoring patient,
Mesenteric venous thrombosis, 1039 (MEMS), 59, 61, 61ft 1120–1121
Meta-analysis of ECMO trials and Monoclonal antibodies, 604 surgical airway, 1117–1118, 1117f
ARDS, 478–479 Monocyte dysfunction, 555 ventilation, 1118

Index.indd 1347 23-01-2015 15:33:53